8-K: Zivo Bioscience Sells 169,022 Shares in Private Placement

Zivo Bioscience sold 169,022 shares of common stock to accredited investors between August 22 and October 17, 2024, raising capital through a private placement.

Summary

• Zivo Bioscience, Inc. sold 169,022 shares of its common stock between August 22, 2024, and October 17, 2024.
• The shares were sold to accredited investors at prices ranging from $8.34 to $16.31 per share, with an average price of $10.44 per share.
• A total of 52,802 shares were sold to related parties at prices between $8.34 and $15.96, averaging $9.68 per share.
• The sale was conducted as a private placement, exempt from registration under the Securities Act of 1933.
• No solicitation was made, and no underwriting discounts were given or paid.
• As of October 17, 2024, the company has 3,535,134 common stock shares outstanding.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company successfully raised capital, but the private placement may dilute existing shareholders. The sale to related parties is a positive sign.

Positives

• The company successfully raised capital through a private placement.
• The sale of shares to related parties indicates confidence in the company's prospects from insiders.

Risks

• The sale of unregistered shares could potentially dilute existing shareholders' ownership.
• The reliance on private placements for funding may indicate challenges in accessing public markets.

Industry Context

Private placements are a common method for smaller companies to raise capital, especially when access to public markets is limited or costly. This is a typical approach for companies in the biotechnology sector.

Comparison to Industry Standards

• Private placements are a common method for raising capital in the biotechnology industry, particularly for companies that are not yet profitable or have limited access to public markets.
• The pricing of the shares in this private placement is within the typical range for similar companies, although the specific valuation depends on the company's stage of development and perceived risk.
• Comparable companies often use a mix of private and public funding to support their research and development activities.

Related Party Transactions

• 52,802 shares were sold to related parties at prices between $8.34 and $15.96, averaging $9.68 per share.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares.
• The capital raise could enable the company to fund its operations and research, potentially benefiting all stakeholders in the long term.

Key Dates

Keywords

private placement, equity securities, common stock, accredited investors, capital raise, related party transaction, unregistered sales